Today techs Medicenna Proclaims Outcomes of Annual Assembly of

today techs

TORONTO and HOUSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Firm”) (NASDAQ: MDNA TSX: MDNA), a medical stage immuno-oncology firm, at the moment introduced the voting outcomes from the Firm’s annual assembly of shareholders held at the moment, September 21, 2022 (the “Assembly”).

Medicenna is happy to announce that all the nominees listed within the administration proxy round dated August 2, 2022 have been elected as administrators. Every of the administrators was elected with larger than 97% of the votes forged by shareholders current on the today techs Assembly or represented by proxy. The outcomes of the vote are detailed beneath:

Nominee Votes For % of
Votes For
In opposition to
% of Votes
In opposition to
Dr. Fahar Service provider 24,859,038 97.878 538,956 2.122
Mr. Albert Beraldo 24,877,225 97.950 520,768 2.050
Ms. Karen Dawes 24,902,175 98.048 495,818 today techs ; border-left: solid black 1pt ; text-align: right ; vertical-align: middle; vertical-align: top ; “>1.952
Dr. John (Jack) Geltosky 24,728,697 97.365 669,296 2.635
Ms. Rosemina Service provider today techs black 1pt ; text-align: right ; vertical-align: middle; vertical-align: top ; “>24,653,185 97.067 744,808 2.933
Dr. Chandrakant Panchal 24,820,996 97.728 576,997 2.272
Dr. John Sampson 24,840,678 97.806 today techs solid black 1pt ; border-left: solid black 1pt ; text-align: right ; vertical-align: middle; vertical-align: top ; “>557,315 2.194

Medicenna shareholders additionally voted to nominate PricewaterhouseCoopers LLP as auditor of the Firm.

A complete of 57.468% of the issued and excellent widespread shares of the Firm have been represented in particular person and by proxy on the Assembly.

About Medicenna
Medicenna is a medical stage immunotherapy firm centered on today techs the event of novel, extremely selective variations of IL-2, IL-4 and IL-13 Superkines and first in school Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding with out CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating most cancers killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Biuseful ShigherOkine ImmunoTremedys) is designed to boost the power of Superkines to deal with immunologically “chilly” tumors. Medicenna’s IL-4 Empowered Superkine, MDNA55, has been studied in 5 medical trials together with a Part 2b trial for recurrent GBM, the commonest and uniformly deadly type of mind most cancers. MDNA55 has obtained Quick-Observe and Orphan Drug standing from the FDA and FDA/EMA, respectively.

Additional Info

For additional details about the Firm please contact:

Elizabeth Williams, Chief Monetary Officer, 416-648-5555,

Investor Contact

For extra investor info, please contact:

Dan Ferry, Managing Director, LifeSci Advisors, 617-430-7576,

today techs
today techs

Be the first to comment

Leave a Reply

Your email address will not be published.